News & Updates

For individuals with dry and itchy eye complaints, engaging in aerobic exercise can bring major relief, a study has found.

New drug applications approved by US FDA as of 16-31 January 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with topical recombinant human nerve growth factor (rhNGF) is safe and well tolerated but falls short of providing neuroprotection in patients with glaucoma, according to the results of a phase Ib study.

Patients with ocular hypertension appear to fare well with mindfulness-based stress reduction (MBSR), which a recent study has shown to result in reductions in intraocular pressure (IOP) and cortisol levels, as well as improvements in optic nerve head perfusion and quality of life.

At a dose of 6 mg, brolucizumab yields substantial visual gains and anatomical improvements in patients with diabetic macular oedema without increasing the risk of serious adverse ocular events when compared with aflibercept, according to data from two phase III trials.

Real-world data show that aflibercept effectively improves visual acuity (VA) outcomes in patients with diabetic macular oedema. However, factors such as age, baseline VA, and deprivation may affect the effectivity of aflibercept.

Post-traumatic endophthalmitis in children is most commonly caused by Streptococcus pneumoniae, though the dominant species tends to vary greatly between age groups, a recent study has found. Visual outcomes in infected children remain poor even despite prompt treatment.